Ramin Mousavi is Named Executive Chairman of NeuWire Medical

NeuWire Medical has appointed Ramin Mousavi as executive board chairman. The designation, officials say, is key as the company prepares to advance its clinical, regulatory, and financing strategy.

Mousavi joins NeuWire Medical following his role as president, CEO, and board member of CathWorks, where he led the company through a strategic partnership, global co-promotion agreement, landmark clinical trial, and eventual acquisition by Medtronic.

NeuWire is developing a closed-loop neuromodulation therapy designed to improve functional recovery in stroke survivors living with chronic motor deficits. The company’s technology pairs vagus nerve stimulation with targeted rehabilitation exercises, using an ultra-miniaturized, wireless, battery-free implant and intelligent stimulation timing to support neuroplasticity during therapy.

“I am very excited to join NeuWire Medical at this important moment,” Mousavi said. “The progress achieved by Rob Rennaker and the team over the past years is impressive, both scientifically and clinically. NeuWire Medical is addressing one of the largest unmet needs in rehabilitation, and I look forward to supporting the company as it steps into its next chapter.”

NeuWire Medical is led by Co-Founder/CEO Rob Rennaker, Ph.D., who has been involved in the research and development of the company’s technology for over a decade. His work, together with collaborators in the field, has helped establish the scientific and clinical foundation for NeuWire Medical’s closed-loop VNS approach in post-stroke recovery.

“We are thrilled to welcome Ramin as executive chairman at this time. With an exceptional history of turning vision into results, Ramin is the ideal executive chairman to guide our next chapter of growth and value creation for NeuWire Medical,” Dr. Rennaker commented.

Mousavi’s appointment follows the publication of clinical results (in Stroke) from the company’s pilot study. The double-blinded, randomized, sham-controlled trial evaluated a miniaturized closed-loop VNS system in individuals with chronic ischemic stroke and residual upper limb deficits. The published data reported a favorable safety and feasibility profile and statistically significant improvements in upper limb motor function following active closed-loop VNS therapy. The authors concluded the system merits evaluation in a larger study.

“These results are an important validation point for our company,” Dr. Rennaker stated. “Our goal is to help stroke survivors achieve greater recovery by combining rehabilitation with precisely timed neuromodulation at home and in the clinic. We are now focused on securing the financing required to execute the pivotal study required to bring this therapy closer to patients.”

NeuWire Medical is preparing to raise capital to support its U.S. Food and Drug Administration (FDA) IDE pivotal clinical study, regulatory activities, manufacturing scale-up, and preparation for future commercialization.

NeuWire Medical is developing a next-generation closed-loop vagus nerve stimulation platform for post-stroke rehabilitation. The system uses a miniature, wireless implant that delivers stimulation during high-quality therapeutic movements. By pairing active rehabilitation with precisely timed neuromodulation, NeuWire aims to enhance targeted neuroplasticity and improve functional recovery for stroke survivors.

NeuWire Medical’s VNS implant system is an investigational device and has not been approved or cleared by the FDA. The device is limited by U.S. law to investigational use.